Oppenheimer Rates Eupraxia Pharmaceuticals (EPRX) buy

Oppenheimer maintains its buy rating for Eupraxia Pharmaceuticals, setting a price target of $17, a 157.97% upside from the current price.

By EarningsIQ Research Desk · Published Jun 27, 2026, 3:03 AM EDT · Updated Jun 30, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer rated Eupraxia Pharmaceuticals Inc. ($EPRX) "buy" with a $17 price target on June 26, 2026.

Since the rating, $EPRX is down 1.2% after 1 week, down 6.5% after 1 month and up 0.3% to date (from the $6.60 close on Jun 26, 2026).

EPRX Eupraxia Pharmaceuticals Inc.

$6.62 -12.55% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer reiterated its buy rating for Eupraxia Pharmaceuticals on June 26, 2026, with a price target of $17.
Oppenheimer's $17 price target implies 157.97% upside from Eupraxia Pharmaceuticals Inc.'s ($EPRX) current $6.59 share price.
Shares of EPRX traded near $6.41 on Saturday, with a market cap of $431.2 million and a beta of 1.477.
Analysts from Oppenheimer, Stifel, and HC Wainwright & Co. have all set buy ratings with targets ranging from $11 to $25.

Get $EPRX trade alerts by text

We text you when insiders, Congress or big funds trade $EPRX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Eupraxia Pharmaceuticals Inc. alert may contain errors. Disclosures

Oppenheimer reiterated its buy rating on Eupraxia Pharmaceuticals Inc. (NasdaqCM: EPRX) on June 26, 2026. The firm set a price target of $17, maintaining a positive outlook on the stock. Eupraxia shares were trading around $6.41 on Saturday.

Analyst rating track record

Oppenheimer vs. the S&P 500

YTD return +30.88% hypothetical

All-time return +104.10% S&P 500 +27.41%

vs. S&P 500 +76.69% ahead of the index

Hypothetical returns from Oppenheimer's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Eupraxia Pharmaceuticals

Several institutional investors have shown interest in Eupraxia Pharmaceuticals. Affinity Asset Advisors, LLC increased its holdings significantly by 1,289,005 shares, now owning 1,589,005 shares valued at approximately $11.5 million. Meanwhile, Ikarian Capital, LLC also boosted its stake by 604,741 shares, bringing its total to 1,214,741 shares worth about $8.8 million. On the other hand, Beutel, Goodman & Co Ltd. trimmed its position by 42,908 shares, now holding 3,666,465 shares valued at $26.4 million.

Eupraxia Pharmaceuticals Inc. Stock Down 23.2%

Shares of Eupraxia Pharmaceuticals Inc. traded near $6.41 on Saturday. The company has a market capitalization of approximately $431.2 million. It operates with a beta of 1.477, indicating a higher volatility compared to the market. The stock's 52-week range is between $4.67 and $9.32, and it has a 50-day moving average of $6.87 and a 200-day moving average of $6.92. The company is not currently profitable, as reflected by its negative forward P/E ratio of -7.33.

12-month forecast

$EPRX price target

Eupraxia Pharmaceuticals Inc. daily closes and this analyst's $17 target. Not advice.

Analysts Set New Price Targets

On June 26, 2026, Oppenheimer reiterated its buy rating on Eupraxia Pharmaceuticals with a price target of $17. Earlier, on May 21, 2026, Stifel initiated coverage with a buy rating and a $25 target. HC Wainwright & Co. maintained its buy rating on March 17, 2026, with a target of $11. The consensus among nine analysts is a strong buy, with a mean price target of $16.28.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Victoria, Canada. It focuses on developing products for therapeutic areas with unmet medical needs. The company uses its proprietary Diffusphere technology to optimize drug delivery. Its leading product, EP-104IAR, is in Phase III trials for knee osteoarthritis, while EP-104GI is in Phase II for eosinophilic esophagitis. The company is led by CEO Dr. James A. Helliwell and employs around 49 people.

Bottom Line

Eupraxia Pharmaceuticals continues to attract attention from analysts and institutional investors, with Oppenheimer reiterating a buy rating and setting a $17 price target. The stock's recent trading activity and institutional moves suggest ongoing interest in its development pipeline. As a clinical-stage company, its future performance will largely depend on the outcomes of its trials and regulatory milestones.